NasdaqGS:SGMO

Stock Analysis Report

Executive Summary

Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Sangamo Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.4%

SGMO

1.7%

US Biotechs

0.5%

US Market


1 Year Return

-40.1%

SGMO

-7.2%

US Biotechs

6.8%

US Market

Return vs Industry: SGMO underperformed the US Biotechs industry which returned -7.2% over the past year.

Return vs Market: SGMO underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

SGMOIndustryMarket
7 Day1.4%1.7%0.5%
30 Day-22.0%-3.4%-0.8%
90 Day-29.8%-1.3%-0.9%
1 Year-40.1%-40.1%-6.3%-7.2%9.2%6.8%
3 Year110.5%110.5%14.8%10.9%45.6%36.2%
5 Year-26.7%-26.7%-2.3%-7.0%63.2%45.4%

Price Volatility Vs. Market

How volatile is Sangamo Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sangamo Therapeutics undervalued compared to its fair value and its price relative to the market?

2.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SGMO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SGMO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SGMO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SGMO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SGMO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SGMO is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Sangamo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-5.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGMO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SGMO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SGMO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SGMO's revenue (34.1% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: SGMO's revenue (34.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SGMO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Sangamo Therapeutics performed over the past 5 years?

-21.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SGMO is unprofitable, and losses have increased over the past 5 years at a rate of -21.3% per year.

Accelerating Growth: Unable to compare SGMO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: SGMO has a negative Return on Equity (-23.47%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SGMO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SGMO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Sangamo Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SGMO's short term assets ($461.8M) exceeds its short term liabilities ($82.0M)

Long Term Liabilities: SGMO's short term assets (461.8M) exceeds its long term liabilities (145.7M)


Debt to Equity History and Analysis

Debt Level: SGMO is debt free.

Reducing Debt: SGMO has not had any debt for past 5 years.


Balance Sheet

Inventory Level: SGMO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SGMO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SGMO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SGMO has sufficient cash runway for 2.348032 years if free cash flow continues to reduce at historical rates of -3.3% each year.


Next Steps

Dividend

What is Sangamo Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SGMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SGMO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SGMO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGMO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SGMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sangamo Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Sandy Macrae (56yo)

3.3yrs

Tenure

US$4,104,428

Compensation

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch.B, Ph.D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019. Dr. Macrae has been the Chief Executive Office ...


CEO Compensation Analysis

Compensation vs. Market: Sandy's total compensation ($USD4.10M) is about average for companies of similar size in the US market ($USD2.70M).

Compensation vs Earnings: Sandy's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.0yrs

Average Tenure

50yo

Average Age

Experienced Management: SGMO's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

63.5yo

Average Age

Experienced Board: SGMO's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$18,00216 Nov 18
H. Parker
EntityIndividual
Role
Chairman of the Board
Chair of the Board
Shares2,000
Max PriceUS$9.00

Ownership Breakdown


Management Team

  • McDavid Stilwell

    Senior Vice President of Corporate Communications & Investor Relations

    • Tenure: 2.9yrs
  • Ed Rebar

    Senior VP & CTO

    • Tenure: 1.3yrs
  • Andy Ramelmeier

    Executive Vice President of Technical Operations

    • Tenure: 1.6yrs
  • Gary Loeb (49yo)

    Executive VP & General Counsel

    • Tenure: 0.3yrs
  • Stéphane Boissel (51yo)

    Interim CFO & Executive VP of Corporate Strategy

    • Tenure: 0.3yrs
    • Compensation: US$2.59m
  • Nathalie Dubois-Stringfellow

    Senior Vice President of Product Development & Management

    • Tenure: 0.8yrs
  • Sandy Macrae (56yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$4.10m
  • Heather Erickson

    Chief of Staff

    • Tenure: 3.3yrs
  • Prathyusha Durabaibu (40yo)

    Principal Accounting Officer

    • Tenure: 0.3yrs
  • Julie Person

    Vice President of Human Resources

    • Tenure: 0.6yrs

Board Members

  • Mike Gilman (64yo)

    Member of Scientific Advisory Board

    • Tenure: 13.3yrs
  • H. Parker (63yo)

    Chair of the Board

    • Tenure: 2.3yrs
    • Compensation: US$277.77k
  • Barrie Carter (74yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Stephen Dilly (59yo)

    Independent Director

    • Tenure: 9.6yrs
    • Compensation: US$235.27k
  • Aaron Klug (92yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Bob Carey (60yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$250.27k
  • Gabor Rubanyi (72yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Kevin Struhl

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Judy Campisi

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Sandy Macrae (56yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$4.10m

Company Information

Sangamo Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sangamo Therapeutics, Inc.
  • Ticker: SGMO
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$961.838m
  • Shares outstanding: 115.68m
  • Website: https://www.sangamo.com

Number of Employees


Location

  • Sangamo Therapeutics, Inc.
  • 501 Canal Boulevard
  • Richmond
  • California
  • 94804
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SGMONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2000
GBYDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2000
0R1DLSE (London Stock Exchange)YesCommon StockGBUSDApr 2000

Biography

Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therap ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 23:42
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.